Actively Recruiting
Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
Led by Guangdong Provincial People's Hospital · Updated on 2025-02-21
120
Participants Needed
1
Research Sites
47 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
EGFR-mutated NSCLC is a distinct subtype that responds well to targeted therapies. Neoadjuvant targeted therapy aims to downstage tumors and improve surgical outcomes, but the prognostic role of residual viable tumor (RVT) remains unclear. This retrospective study examines the association between RVT and survival outcomes. The findings will further validate the importance of RVT as a surrogate.
CONDITIONS
Official Title
Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-80 years old
- Pathologically diagnosed EGFR-mutated non-small cell lung cancer (NSCLC)
- Treated with neoadjuvant targeted therapy
- Undergoing definitive surgery
You will not qualify if you...
- History of prior chemotherapy, immunotherapy, or radiotherapy
- History of malignancy or lung surgery
- Missing key data
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China, 510080
Actively Recruiting
Research Team
G
Guibin Qiao
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here